Drug intelligence / Profile preview

bismuth-206

Development stage
Preclinical
Lead developer
University of Wisconsin–Madison
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Bismuth-206 is a cyclotron-produced radioactive isotope of bismuth with a half-life of approximately 6.24 days. It is primarily utilized in preclinical research as a diagnostic SPECT (single-photon emission computed tomography) imaging radiotracer and surrogate to evaluate the biodistribution and renal redistribution of bismuth daughter radionuclides (such as bismuth-212 and bismuth-213) generated during targeted alpha therapy (TAT) with actinium-225 or lead-212. Because bismuth naturally accumulates in renal proximal tubule epithelial cells, leading to potential nephrotoxicity, bismuth-206 serves as an imaging tool to investigate remediation strategies, such as cold metal blockade (e.g., using iron) and metal sequestration (e.g., using chelating agents like DMSA or DMPS), to reduce renal accumulation and improve the safety profile of TAT.

Other names
206BiBi-206Bi206Bi 206[206Bi]Bi[206Bi]bismuthbismuth 206bismuth206bismuth-206
02

Identity

Drug type
Radiopharmaceuticals
Modality
Antibody-Based TherapeuticsAntibody-Radionuclide Conjugates
03

Pharmacology

Route
Intravenous
04

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

05

Companies

  • University of Wisconsin–MadisonLead developer
06

Competitive landscape

Drugs on the same target
281

Most advanced

  1. amifostineApproved
  2. bendamustineApproved
  3. bleomycinApproved
  4. bleomycin A2Approved
  5. busulfanApproved

Beyond the preview

Go deeper on bismuth-206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bismuth-206.

Work on bismuth-206? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call